Aussie Suits Against Merck's Vioxx Go On As First Case Waits Appeal
This article was originally published in PharmAsia News
Australian suits against Merck and its former Vioxx (rofecoxib) arthritis drug continue to move through the courts without waiting for resolution of the first case decided a year ago
You may also be interested in...
The approval is based on the results ABRE clinical study, which showed the stent improved patency iliofemoral veins in 88% of cases with a 2% rate of major adverse events.
Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.